Balanced decision between anti-infective and antitumor therapies and pharmaceutical care for a malignant tumor patient

doi:10.19803/j.1672-8629.20230200

Chinese Journal of Pharmacovigilance ›› 2023, Vol. 20 ›› Issue (10): 1168-1172.
DOI: 10.19803/j.1672-8629.20230200

Balanced decision between anti-infective and antitumor therapies and pharmaceutical care for a malignant tumor patient

WANG Yanting¹, ZHANG Yuanyuan², CHEN Yiran², SUN Jie², ZHU Yu³, YANG Liyan³, WU Zhigui^1,4, SHEN Lijun^1,5, CHENG Min^2,#, LI Guohui^1,*

¹Department of Pharmacy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China;
²Department of Gynecologic Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China;
³Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China;
⁴Department of Pharmacy, Affiliated Hospital of Southwest Medical University, Luzhou Sichuan 646000, China;
⁵Pharmacy Intravenous Admixture Services, Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou Sichuan 646000, China

Received:2023-04-10 Online:2023-10-15 Published:2023-10-16

Abstract

Abstract: Objective To explore the balance between the anti-infective therapy and anti-tumor therapy and pharmaceutical care delivered to a malignant tumor patient by doctors and clinical pharmacists. Methods The roles of clinical pharmacists in the treatment of a case of advanced ovarian cancer were reported. Optimization of treatment focused on the differentiation of infectious fever from neoplastic fever, the selection of anti-microbial drugs, and the pharmaceutical care related to the anti-tumor therapy. Results Clinicians and pharmacists differed considerably in the differential diagnosis of infection and tumor fever for this patient. After multidisciplinary weighing, the anti-tumor therapy was selected and given with priority. Clinical pharmacists gave advice about the diagnosis of infection, risk analysis of the anti-tumor therapy and pharmaceutical care for the anti-tumor therapy so as to ensure the safety and efficacy of the treatment. Conclusion For patients diagnosed with advanced malignant tumor with high infection-related indicators but different diagnosis of infections, the anti-tumor therapy can be the first option, but the risks and benefits should be weighed and the patient should be monitored closely. Clinical pharmacists and doctors can help improve the safety and efficacy of pharmacotherapy by giving full play to their expertise.

Key words: infectious fever, tumor fever, ovarian cancer, anti-infection, chemotherapy, pharmaceutical care

CLC Number:

WANG Yanting, ZHANG Yuanyuan, CHEN Yiran, SUN Jie, ZHU Yu, YANG Liyan, WU Zhigui, SHEN Lijun, CHENG Min, LI Guohui. Balanced decision between anti-infective and antitumor therapies and pharmaceutical care for a malignant tumor patient[J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1168-1172.

References

[1] LIAW CC, CHEN JS, WANG CH, et al.Tumor fever in patients with nasopharyngeal carcinoma: clinical experience of 67 patients[J]. Am J Clin Oncol, 1998, 21(4): 422-425.
[2] ISAZA E, HUPPERT LA, LAI AR, et al.Tumor fever due to metastatic esophageal squamous cell carcinoma[J]. Am J Med, 2022, 135(8): e294-e295.
[3] WU YY, ZHANG HL.Meta-analysis of efficacy of naproxen in treating tumor fever[J]. Journal of Guangxi Medical University(广西医科大学学报), 2019, 36(7): 1089-1095.
[4] FOGGO V, CAVENAGH J.Malignant causes of fever of unknown origin[J]. Clin Med(Lond), 2015, 15(3): 292-294.
[5] ZHANG X, YANG LL, SHI G, et al.Clinical value of procalcitonin and hypersensitive C-reactive protein in early diagnosis of advanced infection fever and tumor fever[J]. Trauma and Critical Care Medicine(创伤与急危重病医学), 2021, 9(3): 235-236.
[6] PASIKHOVA Y, LUDLOW S, BALUCH A.Fever in patients with cancer[J]. Cancer Control, 2017, 24(2): 193-197.
[7] ODAGIRI T, MORITA T, SAKURAI H, et al.A multicenter cohort study to explore differentiating factors between tumor fever and infection among advanced cancer patients[J]. J Palliat Med, 2019, 22(11): 1331-1336.
[8] TIAN CX, ZHENG WC.Clinical application of procalcitonin in differential diagnosis of infection fever and tumor fever[J]. China Medicine and Pharmacy(中国医药科学), 2020, 10(5): 252-254.
[9] National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology-ovarian cancer inlcuding fallopian tube cancer and primay peritoneal cancer2023 Version 1[EB/OL].[2023-04-01].https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf.
[10] National Health Commission. Ovarian cancer diagnosis and treatment guidelines(2022 edition)(卵巢癌诊疗指南2022年版)[EB/OL].[2023-
04-01]. http://www.nhc.gov.cn/yzygj/s7659/202204/a0e67177df1f439898683e1333957c74/files/0feefc11d98840898b136ac3d9a4ee20.pdf.
[11] Chinese Society of Clinical Oncology Guidelines Working Committee. Chinese Society of Clinical Oncology (CSCO) Ovarian Cancer Diagnosis and Treatment Guidelines 2022
(中国临床肿瘤学会卵巢癌诊疗指南2022) [M]中国临床肿瘤学会卵巢癌诊疗指南2022) [M]. Beijing: People's Medical Publishing House, 2022.
[12] NCCN Chemotherapy Order Templates (NCCN Templates®) Appendix B-Carboplatin Dosing in Adults[EB/OL].[2023-04-01].https://www.nccn.org/docs/default-source/clinical/order-templates/appendix_b.pdf?sfvrsn=6286822e_2.
[13] Lexicomp. Wolters Kluwer[DB/OL].[2023-04-01]. https://www.uptodate.cn/drug-interactions/?source=responsive_home#dianalyze.
[14] ZHAO Z, LI X, ZHAO Y, et al.Role of C-reactive protein and procalcitonin in discriminating between infectious fever and tumor fever in non-neutropenic lung cancer patients[J]. Medicine (Baltimore), 2018, 97(33): e11930.
[15] WANG YY, JIN HR, WANG ZG.Significance of clinical indicators such as PCT in differentiating infectious fever from tumor fever in advanced cancer patients[J]. Journal of Pathogen Biology(中国病原生物学杂志), 2018, 13(5): 532-535.
[16] HANGAI S, NANNYA Y, KUROKAWA M.Role of procalcitonin and C-reactive protein for discrimination between tumor fever and infection in patients with hematological diseases[J]. Leuk Lymphoma, 2015, 56(4): 910-914.

Balanced decision between anti-infective and antitumor therapies and pharmaceutical care for a malignant tumor patient

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

[1]	FANG Meilin, ZHENG Huimin, WANG Cunze, WANG Ling, RUAN Junshan. One case of generalized myalgia caused by oxaliplatin [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 208-210.
[2]	ZHANG Xialan, YUAN Jing, WU Bin, QIN Yuanyuan. Medications of apatinib mesylate in patients with malignant tumors [J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 927-932.
[3]	WANG Ran, LI Yifan, LIU Xiaoyan, FENG Xin. One case of pharmaceutical care of drug exposure during pregnancy [J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 933-934.
[4]	MA Qihong, SHI Yuanyuan, CHEN Fangfang, WU Kang, BU Zixuan, LU Tiangong. Mechanisms of celastrol for ovarian cancer: based on quantitative proteomics [J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 721-727.
[5]	LIU Jing, XIA Liang, ZHANG Shijie. Pharmaceutical care of a patient with acute pancreatitis complicated with multiple drug allergy undergoing drug stimulation test [J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 822-824.
[6]	WANG Ran, FENG Xin, DU Boran. Advances in risk assessment and pharmaceutical care of pregnancy medication exposure during perinatal period [J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 836-840.
[7]	LI Rongrong, LI Meng, GOU Yue, LUO Qiong, LYU Hua, SUN Xin, LIU Chenghai. Clinical characteristics and risk factors of 113 cases of anti-neoplastic drug-induced liver injury [J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 505-510.
[8]	FAN Xiucong, DONG Xiaohui, CHEN Danxia, BAO Siwei, MA Yabin. Pharmaceutical care of a patient with Clostridium difficile infection and urinary tract infection during pregnancy [J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 579-582.
[9]	HUO Peiqiong, ZHENG Peng, SU Zhenhao. Pharmacovigilance in retail pharmacies for special or major diseases [J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 428-432.
[10]	BAO Lei, GENG Zihan, GUO Shanshan, YAO Rongmei, SUN Jing, CUI Xiaolan. Effect of Reyanning Heji on animal models of respiratory infectious inflammation [J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 241-247.
[11]	JIAO Fuzhi, CHEN Yarui, JI Wei, HAO Jianpeng, GUAN Quanlin. Short-term efficacy and safety evaluation of PD-1 inhibitor combined with chemotherapy as a first-line neoadjuvant therapy for locally advanced gastric adenocarcinoma [J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 301-305.
[12]	YANG Yan, ZHOU Dexi, WU Xinli, XUE Shuya, DING Haihua, ZHANG Quan, ZHANG Yunling. Eighty-four cases of adverse drug reactions caused by novel anti-tumor drugs [J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 334-338.
[13]	YAO Xin, GE Qiuge, LI Yamin, WANG Yifan, LI Yuanyuan, LIU Zhiqiang. Adverse drug reactions caused by new anti-tumor drugs from 2018 to 2022 in one hospital [J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1273-1278.
[14]	ZHENG Jinfeng, WANG Jinghong. Pharmaceutical care of one case of malignant arrhythmia induced by multidrug combination [J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1279-1281.
[15]	SU Su, WU Shiqi, ZHANG Qingxia, YAN Suying. Pharmaceutical care of a patient with indapamide-induced agranulocytosis [J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1282-1285.